VIP
VIP (vasoactive intestinal peptide) is supplied as a VPAC1/VPAC2 receptor-signaling reference material for neuro-immune pathway research. Supplied strictly for laboratory and educational research. Not for human or veterinary use.
Vial amount
Purchase option
Checkout includes a research-use attestation. Materials are supplied only for laboratory and educational research.
VIP in research
VIP (vasoactive intestinal peptide) is supplied as a VPAC1/VPAC2 receptor-signaling reference material for neuro-immune pathway research.
General RUO catalog item for documented laboratory workflows.
Bench context
Supplied as a research-grade reference material for documented laboratory and educational research workflows.
Available amounts
Select from the stocked vial amounts for VIP before adding the material to cart.
Claims discipline
No protocol instructions, no dosing, no medical advice, and no therapeutic or human-use promises.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, not for diagnostic or therapeutic use, not a drug or supplement.
As listed by the supplier in BioRegen's ordering system, shown here exactly as written for transparency. This is the vendor's own description, not independently verified, edited, or endorsed by BioRegen, and is not a BioRegen claim of any effect.
Standard
Vasoactive Intestinal Peptide
The full research picture, clearly labeled
BioRegen reports the entire research landscape for this compound across four clearly separated tiers, strongest evidence first. Lower tiers, including community and anecdotal reports, are labeled as such and are not BioRegen claims.
VIP (Vasoactive Intestinal Peptide) is an endogenous signaling peptide, and its synthetic analog aviptadil (developed under the names RLF-100 and ZYESAMI by NRx Pharmaceuticals/NeuroRx and Relief Therapeutics) has been investigated in human trials, primarily for respiratory failure in COVID-19-related acute respiratory distress syndrome (ARDS) and historically for pulmonary arterial hypertension. According to investigators and sponsor reports, aviptadil was studied under U.S. FDA Expanded Access and IND authorizations and advanced into Phase 2b/3 testing, with some sponsor-reported analyses describing survival and recovery signals; these were also supported by NIH/BARDA-funded research (the ACTIV-3b/TESICO program). Independent and trial outcomes have been mixed and remain a subject of ongoing scientific debate, and the overall human evidence base for VIP outside these specific respiratory contexts is limited. Readers should consult the peer-reviewed and registry literature directly rather than rely on any single sponsor statement.
Preclinical research characterizes VIP as a widely distributed neuropeptide that is highly concentrated in lung tissue and that acts on VPAC1 and VPAC2 receptors, where laboratory and animal studies report roles in vasodilation, anti-inflammatory cytokine modulation, and surfactant-related pathways. Investigators have studied these mechanisms in cell-culture and animal models of inflammation and pulmonary injury, which provided the stated rationale for later human investigation of the synthetic analog. As with most preclinical findings, results in laboratory systems do not establish effects in humans.
Within biohacker communities, longevity forums, and some mainstream media coverage tied to the COVID-19 period, VIP and aviptadil have been discussed in the context of lung, inflammatory, and recovery topics, with attention amplified by sponsor press releases and trial news. Such discussion reflects public interest and individual commentary rather than systematic evaluation, and reported personal experiences are inconsistent and uncontrolled. This material is unverified anecdotal commentary, not controlled data, and not a BioRegen claim.
VIP is an endogenous human peptide, and its synthetic analog aviptadil remains investigational: it has received U.S. FDA Fast Track designation and orphan drug designations (for indications including ARDS, pulmonary hypertension, and sarcoidosis) but is not FDA-approved for any use, and no VIP product is approved as a general therapeutic. Designations such as Fast Track or orphan status reflect a development pathway, not a determination of safety or efficacy. BioRegen supplies it strictly for laboratory and educational research, not for human use.
Tiers are evidence categories, not endorsements. Clinical and preclinical entries summarize third-party published research. Community and anecdotal entries are unverified reports discussed by others, not findings and not BioRegen claims. Nothing here is medical advice, and no compound is approved for human or veterinary use except where explicitly stated under Regulatory status.
What the published research says about VIP
This section reports on published research referenced in BioRegen's own research library. It is not a claim by BioRegen that the compound provides any benefit, and nothing here is medical advice.
- Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids, 2011.
- Vasoactive Intestinal Peptide (VIP) Protects Nile Tilapia against Infection. International Journal of Molecular Sciences, 2022.